Overview

Expedition Medicines designs small molecule drugs for hard-to-drug protein targets using AI and quantum chemistry. Its platform blends quantum-chemistry analysis with chemoproteomics to pursue a reaction-first, covalent binding strategy rather than a traditional binding-first approach. It differentiates itself by applying covalent and generative chemistry with AI-driven design and by pursuing major pharma collaborations, such as a Pfizer multi-target exploration agreement. Its goal is to build a pipeline of first-in-class therapies in oncology and immunology and to advance drug candidates into preclinical and clinical development through internal programs and partnerships.